Measurement of urinary leukotrienes by reversed-phase liquid chromatography and radioimmunoassay.
Leukotriene (LT) E4, an important LT metabolite appearing in urine, can be rapidly separated from normal and pathological urines by automated reversed-phase HPLC after a simple sample-processing. The recoveries of LTE4 afforded by this system (86.4 +/- 6.5%, mean +/- SEM for 60 ng/L, 85.4 +/- 0.3% for 200 ng/L) are superior to those obtained by a manual extraction method. Consistency of results is similar. Highly reproducible retention times combined with a radioimmunoassay allow one to identify (based on co-elution) and quantify as little as 8 ng/L LTE4 in a 10-mL urine sample. LTE4 concentrations in urine from healthy persons approach this value (17 +/- 5 ng/L), whereas samples from patients with cardiac ischemia show a wider range of concentrations (8 to 388 ng/L), up to 50 times the detection limit. Thus this method is applicable to the noninvasive investigation of leukotriene involvement in a wide range of ischemic, inflammatory, and hypersensitive conditions.
Tagari
P
P
Merck Frosst Centre for Therapeutic Research, Department of Pharmacology, Pointe Claire-Dorval, Quebec, Canada.
Ethier
D
D
Carry
M
M
Korley
V
V
Charleson
S
S
Girard
Y
Y
Zamboni
R
R
D002851:Chromatography, High Pressure Liquid; D003327:Coronary Disease / Q000652:urine*; D006801:Humans; D017999:Leukotriene E4; D013189:SRS-A / Q000031:analogs & derivatives* / Q000652:urine*
D013189:SRS-A; D017999:Leukotriene E4